35 active trials 26 recruiting 14 disease areas 1 changes in 30 days
| Early Phase 1 | 3 | |
| Phase 1 | 8 | |
| Phase 1/2 | 9 | |
| Phase 2 | 4 | |
| Phase 4 | 1 |
| NCT ID | Title | Condition | Status | Updated |
|---|---|---|---|---|
| Phase 4 | ||||
| NCT07014540 | A Irinotecan Liposome Trial of in Advanced Neuroendocrine Carcinoma | Neuroendocrine Carcinomas (NEC) | Not Yet Recruiting | 2025-06-11 |
| Phase 2 | ||||
| NCT06433609 | Study of ADCs Combined With Adebrelimab in HER2-negative Advanced Breast Cancer | Advanced Breast Cancer | Recruiting | 2026-07-14 |
| NCT07688291 | A Phase II Study of PD-1/IL-2α-bias Bispecific Antibody Fusion Protein Monotherapy in… | Esophageal Squamous Carcinoma Cell | Not Yet Recruiting | 2026-07-07 |
| NCT07520357 | A Phase II Clinical Study of SHR-A1904 Monotherapy in Second-Line or Later Treatment of… | Advanced Neuroendocrine Carcinoma | Not Yet Recruiting | 2026-04-09 |
| NCT06951243 | A Trial of MHB088C in Advanced Extrapulmonary Neuroendocrine Cancer | Advanced Extrapulmonary Neuroendocrine Cancer | Not Yet Recruiting | 2025-04-30 |
| Phase 1/2 | ||||
| NCT07022964 | CD5 CAR T-Cell Therapy for r/r T-cell Lymphomas | T-Cell Non-Hodgkin Lymphoma | Recruiting | 2026-09-11 |
| NCT06947460 | CD19-BCMA CART Cell Therapy for Refractory SLE-LN, SSc, and pSS-PAH | Refractory Lupus Nephritis | Recruiting | 2026-07-30 |
| NCT06316856 | CD5 Chimeric Antigen Receptor (CAR) T Cells in Subjects With Relapsed or Refractory… | T-Cell Acute Lymphocytic Leukemia | Recruiting | 2026-03-10 |
| NCT06585514 | Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory Systemic Lupus Erythematosus | Systemic Lupus Erythematosus (SLE) | Recruiting | 2026-03-10 |
| NCT06688799 | Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory Autoimmune Diseases | Autoimmune Diseases | Recruiting | 2026-03-10 |
| NCT06947473 | Umbilical Cord Blood CD19-BCMA CART Cell Therapy for SLE-LN, SSc, andpSS PAH. | Refractory Lupus Nephritis | Recruiting | 2026-03-03 |
| NCT06316427 | Autologous and Donor-derived CD7 CAR-T Therapy in Refractory or Relapsed T-cell… | T-cell Acute Lymphoblastic Leukemia | Recruiting | 2025-11-26 |
| NCT07070323 | A Multicenter, Open-Label, Non-Randomized, Single-Arm Clinical Study of Nanobody CD5-CAR… | T-Cell Acute Lymphocytic Leukemia | Recruiting | 2025-11-26 |
| NCT06925464 | CD7 CAR T-Cell Therapy for r/r T-cell Lymphomas | T-Cell Non-Hodgkin Lymphoma | Recruiting | 2025-05-13 |
| Phase 1 | ||||
| NCT06326021 | Optimised CD33 (FL-33) CAR T Therapy for Refractory/Relapsed Acute Myeloid Leukaemia | Refractory/Relapsed Acute Myeloid Leukaemia | Recruiting | 2026-05-22 |
| NCT06822881 | CT1190B in the Treatment of Patients With Moderate to Severe Refractory Systemic Lupus… | Systemic Lupus Erythematosus (SLE) | Recruiting | 2026-03-10 |
| NCT06326008 | Safety, Tolerability, and Pharmacokinetics of Donor-derived CD19 CAR Therapy Bridged… | B-cell Acute Lymphoblastic Leukemia | Recruiting | 2026-03-09 |
| NCT07329894 | Safety, Tolerance and Preliminary Efficacy of XH001 Injection Combined With Neoantigen… | Gastrointestinal Cancer | Recruiting | 2026-02-12 |
| NCT07003555 | Dual-target BCMA-CD19 CAR-T Cell Therapy for RR/MM With Extramedullary Infiltration | Relapsed or Refractory Multiple Myeloma (RRMM) | Recruiting | 2025-11-26 |
| NCT07003568 | Dual-target BCMA-GPRC5D CAR-T Cell Therapy for RR/MM With Extramedullary Infiltration | Relapsed or Refractory Multiple Myeloma (RRMM) | Recruiting | 2025-11-26 |
| NCT07167537 | A Study of OL-CD19-GDT in Relapsed/ Refractory Autoimmune Diseases | Systemic Sclerosis (SSc) | Recruiting | 2025-09-11 |
| NCT06980597 | A Study of OL-108 in Relapsed/Refractory Autoimmune Diseases | Systemic Lupus Erythematosus (SLE) | Recruiting | 2025-05-20 |
| Early Phase 1 | ||||
| NCT06890494 | Clinical Study on the Safety and Efficacy of BiTE-EV in Relapsed/Refractory Acute B-Cell… | Leukemia | Recruiting | 2026-03-10 |
| NCT07242417 | TC-G203 for Patients With GPC3-Positive Advanced Solid Tumors | Solid Cancer | Recruiting | 2026-01-21 |
| NCT07093411 | Targeting CD19/CD20 Dual-targeted Cell in Patients With Relapsed/Refractory B-cell… | B-cell Non-Hodgkin Lymphoma Recurrent B-cell Non-Hodgkin Lymphoma Refractory | Recruiting | 2025-08-20 |
Leukemia (8) · Acute Lymphoblastic Leukemia (ALL) (6) · Lupus (SLE) (6) · Non-Hodgkin Lymphoma (5) · Scleroderma (5) · Hypertension (2) · Multiple Myeloma (2) · Acute Myeloid Leukemia (AML) (1) · Breast Cancer (1) · Esophageal Cancer (1)